PTCT

PTC Therapeutics had a breakout FY2025, swinging from years of losses to GAAP net income of $683M on revenue of $1.73B (+114.5%) and operating income of $867M (a 50.1% operating margin). The inflection is real and product-driven: the 10-K details the global launch of Sephience (sepiapterin) for PKU, approved in 2025 by the EC, FDA, Japan's MHLW and Brazil's ANVISA ($111.2M of net product revenue in its first partial year), alongside established DMD franchises Translarna ($235.3M) and Emflaza ($146.4M). Operating cash flow surged to $711M, and cash grew 26.3% to $985M.

The step-change in revenue and earnings, however, looks partly driven by large one-time or milestone/partnership items rather than purely recurring product sales — recurring named product revenue ($111M + $235M + $146M) is well below the $1.73B total, implying a significant non-product/upfront component that may not repeat. The R&D cut of 14.8% to $455M also suggests a focusing of spend. The negative stockholders' equity (-$205M) and -$2.96B accumulated deficit reflect the long history of losses, not current distress given the now-strong cash flow.